Pharma stock gets EU nod to sell paracetamol; up 10%

Shares of Medicamen Biotech rose 10% over two sessions after the company announced EU registration approval for paracetamol from the Danish Medicines Authority and a partnership with XGX Pharma, Denmark. The approval opens access to tightly regulated European markets, strengthens Medicamen’s export-driven growth strategy, and creates an opportunity to scale high-volume revenue.